Skip to content
The Chandler Joint Ledger
A research ledger for moving joints

The Chandler Joint Ledger

What to know before trying a newer joint option

Are newer joint treatments likely to ease your soreness? Some people may feel better, but newer care isn't better for everyone. Good proof means treated people improved more than those who did not get it, with both groups checked the same way. Less soreness does not mean worn tissue grew back.

A study can show relief, only hint at relief, or leave the question unanswered. Relief is shown when a careful comparison finds a change people can feel; it is only hinted at when the study is small. The answer stays unknown when the relief was slight, lasted too briefly to judge or wasn't measured.

What to ask about biologic therapies made from blood or tissue

Biologic therapies use part of your own blood or tissue during care at a clinic. PRP and concentrated PRP are blood drawn from you, then spun so platelets become more concentrated. Results can differ because the platelet amount and the way the blood is prepared also differ.

Ask exactly how your blood will be prepared and what change is expected. Is the aim to calm soreness, make movement easier or both? Ask how many people noticed relief and whether it lasted. You need those plain answers before paying for care.

What to keep doing while you decide

New findings haven't replaced gentle strength work and steady movement. Sleep and rest between harder chores still matter, and these steps reveal whether another treatment makes walking easier. Keep doing what helps without forcing a swollen joint.

For one painful activity, note the time until aching settles. Use the same activity each time, such as rising from a chair. Bring the note when discussing natural pain treatments made from your blood or tissue. If you hear joint preservation, ask whether that means easier use, delayed surgery or something else.

Sources

  1. In a 68-week double-blind placebo-controlled trial of 407 participants with obesity and moderate knee osteoarthritis, once-weekly semaglutide 2.4 mg produced -13.7% body weight change versus -3.2% with placebo, and a WOMAC pain change of -41.7 points versus -27.5 with placebo (P<0.001 for both), with a greater SF-36 physical-function gain.

    Bliddal H, et al. — Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.. N Engl J Med, 2024. DOI: 10.1056/NEJMoa2403664.

  2. A systematic review and meta-analysis of 25 randomized trials (1,048 participants) found mesenchymal stromal cell therapy for knee OA lowered 12-month pain VAS by 1.91 points versus viscosupplementation and by only 0.99 points versus placebo - and rated the certainty of evidence VERY UNCERTAIN by GRADE for both comparisons. Excluding high-risk-of-bias studies left a similar effect at moderate certainty versus viscosupplementation.

    Tabet CG, et al. — Advanced therapy with mesenchymal stromal cells for knee osteoarthritis: Systematic review and meta-analysis of randomized controlled trials.. J Orthop Translat, 2024. DOI: 10.1016/j.jot.2024.07.012.

  3. A separate 2024 meta-analysis of 18 articles concluded mesenchymal stem cells were superior to placebo for pain relief and function at 12 months in knee osteoarthritis, with no significant difference in treatment-related adverse events - while explicitly listing high heterogeneity and short follow-up as limitations that prevent conclusions about long-term efficacy or safety.

    Tian X, et al. — Relative efficacy and safety of mesenchymal stem cells for osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.. Front Endocrinol (Lausanne), 2024. DOI: 10.3389/fendo.2024.1366297.

  4. A triple-blind randomized within-patient trial injected placental mesenchymal stromal cell-derived extracellular vesicles into one knee and saline into the other in 29 patients with bilateral grade 2-3 knee OA. NO statistically significant difference was detected between the treated and control knees on VAS, WOMAC or Lequesne scores at 2 or 6 months.

    Bolandnazar NS, et al. — Safety and efficacy of placental mesenchymal stromal cells-derived extracellular vesicles in knee osteoarthritis: a randomized, triple-blind, placebo-controlled clinical trial.. BMC Musculoskelet Disord, 2024. DOI: 10.1186/s12891-024-07979-w.

  5. A meta-analysis of eight sham-controlled randomized trials (n=627) found genicular nerve ablation reduced knee OA pain at 12 weeks by 1.65 points versus sham (95% CI -2.57 to -0.74, I2=83%) and improved WOMAC function by 11.37 points, with no serious adverse events reported, in adults ineligible for arthroplasty. Heterogeneity was high and long-term data limited.

    Barreto RB, et al. — Efficacy and safety of genicular nerve ablation techniques for knee osteoarthritis: a systematic review and meta-analysis of sham-controlled randomized trials.. Pain Med, 2026. DOI: 10.1093/pm/pnaf140.

  6. The Global Burden of Disease Study 2021 estimated 595 million people worldwide had osteoarthritis in 2020 - 7.6% of the global population and a 132.2% increase in total cases since 1990 - and projects increases by 2050 of 74.9% for knee, 78.6% for hip, 48.6% for hand and 95.1% for other osteoarthritis sites.

    Global Burden of Disease 2021 Osteoarthritis Collaborators — Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021.. Lancet Rheumatol, 2023. DOI: 10.1016/S2665-9913(23)00163-7.

  7. A meta-analysis of nine randomized trials (898 participants) found dietary interventions improved osteoarthritis pain (SMD -0.67, 95% CI -1.01 to -0.34) and physical function (SMD -0.62). The benefit was concentrated in REDUCED-ENERGY diets (pain SMD -0.85); the Mediterranean diet subgroup did NOT significantly change pain (SMD -0.27, 95% CI -1.14 to 0.60, P=0.54).

    Asadi S, et al. — The effectiveness of dietary intervention in osteoarthritis management: a systematic review and meta-analysis of randomized clinical trials.. Eur J Clin Nutr, 2025. DOI: 10.1038/s41430-025-01622-0.

  8. FDA states verbatim that stem cell products, stromal vascular fraction (adipose-derived), umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products have NOT been approved 'for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells derived from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

    U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

What to ask at a visit

At its Chandler office, QC Kinetix offers consultations with medical providers—clinicians who examine you—and regenerative treatments made from your blood or tissue.

Book an appointment